EUVIMEDEUVIMED entdecken
Crossref

Roflumilast Cream (Zoryve) for Atopic Dermatitis

The Medical Letter on Drugs and Therapeutics · 2024

DOI: 10.58347/tml.2024.1711b ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2024. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Aminopyridines, Phosphodiesterase 4 Inhibitors, Cyclopropanes. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved a 0.15% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of mild to moderate atopic dermatitis (AD) in patients ≥6 years old. Roflumilast is the second PDE4 inhibitor to be approved in the US for treatment of AD; crisaborole (Eucrisa), which can be used in patients ≥3 months old, was the first.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAminopyridinesPhosphodiesterase 4 InhibitorsCyclopropanesBenzamidesHumansSkin CreamAdministration, Cutaneous

Stichwörter der Autor:innen

ElidelEucrisaOpzeluraProtopicZoryveadverse effectsatopic dermatitiscorticosteroidscrisaboroledosagedrug interactionsefficacypimecrolimuspsoriasisroflumilast

Substanzen

RoflumilastAminopyridinesPhosphodiesterase 4 InhibitorsCyclopropanesBenzamides

Zitieren

APA

(2024). Roflumilast Cream (Zoryve) for Atopic Dermatitis. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1711b

Vancouver

Roflumilast Cream (Zoryve) for Atopic Dermatitis. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1711b

BibTeX
@article{euvimed2024,
  title = {Roflumilast Cream (Zoryve) for Atopic Dermatitis},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2024},
  doi = {10.58347/tml.2024.1711b}
}
Kostenlos starten →